Knight Therapeutics exits SXTP stake; 0 shares reported

Rhea-AI Filing Summary

Knight Therapeutics Inc. filed Amendment No. 3 to its Schedule 13G/A as an exit filing for 60 Degrees Pharmaceuticals, Inc. The amendment states that as of March 31, 2026 the reporting person no longer beneficially owns any shares of the issuer's common stock (CUSIP 83006G104).

The filing reports 0 shares beneficially owned and a 0% ownership percentage, and is signed on May 15, 2026 by Samira Sakhia on behalf of Knight Therapeutics Inc.

Insights

Corporate Governance Analyst

Exit filing shows Knight Therapeutics relinquished its stake in the issuer.

The amendment explicitly states that as of March 31, 2026 the reporting person "no longer beneficially owns any shares" of 60 Degrees Pharmaceuticals, with ownership shown as 0 shares and 0%. This is a formal Schedule 13G/A exit filing.

Cash‑flow treatment and reasons for the exit are not provided in the excerpt; subsequent disclosures or transaction filings may specify transfer mechanics or counterparties.

Key Figures

Ownership as of date: March 31, 2026 Shares beneficially owned: 0 shares Percent of class: 0% +3 more

6 metrics

Ownership as of date March 31, 2026 Effective date for exit filing

Shares beneficially owned 0 shares Amount beneficially owned as of March 31, 2026

Percent of class 0% Percent of common stock beneficially owned

CUSIP 83006G104 60 Degrees Pharmaceuticals, Inc. common stock

Form type Schedule 13G/A Amendment No. 3 Filing describing ownership change

Signature date May 15, 2026 Date of signature by Samira Sakhia

Key Terms

Schedule 13G/A, exit filing, beneficially owns, CUSIP

4 terms

Schedule 13G/A regulatory

"Amendment No. 3 to its Schedule 13G/A as an exit filing"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

exit filing regulatory

"This constitutes an exit filing for the Reporting Person"

beneficially owns financial

"the Reporting Person no longer beneficially owns any shares"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

CUSIP technical

"CUSIP No.: 83006G104"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Knight Therapeutics' Schedule 13G/A amendment for 60 Degrees Pharmaceuticals (SXTP) state?

It states Knight Therapeutics holds no shares as of March 31, 2026. The amendment records 0 shares beneficially owned and a 0% ownership stake in 60 Degrees Pharmaceuticals (CUSIP 83006G104), signed May 15, 2026.

What is an "exit filing" on a Schedule 13G/A as used by Knight Therapeutics?

An exit filing notifies the SEC that a holder no longer beneficially owns shares. Here the filing expressly says the reporting person "no longer beneficially owns any shares" as of March 31, 2026, triggering the amendment.

Does the amendment disclose how Knight Therapeutics disposed of its shares in SXTP?

The amendment does not describe the transfer mechanics or counterparties. It only reports the resulting ownership position (0 shares, 0% as of March 31, 2026); sale details are not included in the provided excerpt.

Who signed the Schedule 13G/A Amendment No. 3 for Knight Therapeutics and when?

The form is signed by Samira Sakhia on behalf of Knight Therapeutics Inc. The signature line shows the filing was signed on May 15, 2026 for the amendment declaring the exit position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:02 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

60 Degrees Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

83006G104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 83006G104

1

Names of Reporting Persons

Knight Therapeutics Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) See item 4 below. This constitutes an exit filing for the Reporting Person.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: 60 Degrees Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: 1025 Connecticut Avenue, NW Suite 1000, Washington D.C. 20036
Item 2.
(a)	Name of person filing: Knight Therapeutics Inc.
(b)	Address or principal business office or, if none, residence: 600 - 100 boul. Alexis Nihon Montreal, QC, H4M 2P2
(c)	Citizenship: Canada
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 83006G104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of March 31, 2026, the Reporting Person no longer beneficially owns any shares of common stock of the Issuer. Accordingly, this Amendment No. 3 to Schedule 13G is being filed as an exit filing.
(b)	Percent of class: 0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Knight Therapeutics Inc.

Signature:	/s/ Samira Sakhia
Name/Title:	Samira Sakhia
Date:	05/15/2026